FS
FSNUY.US Fresenius SE & Co KGaA ADR
- Market cap
- USD 33.3B
- P/E
- 18.0x
- P/B
- 1.45x
- ROE
- 7.8%
- Dividend yield
- 2.06%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is FSNUY.US undervalued?
Graham numberFSNUY.US trades 7.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fresenius SE & Co KGaA ADR fundamental analysis
No fundamental analysis for Fresenius SE & Co KGaA ADR yet.
Fresenius SE & Co KGaA ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fresenius SE & Co KGaA ADR
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. I…
Full company profileFresenius SE & Co KGaA ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fresenius SE & Co KGaA ADR annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 29.1B | 33.9B | 33.5B | 35.4B | 36.3B | 37.5B | 40.8B | 22.3B | 21.8B | 22.0B | 23.8B |
| Gross Profit | 9.13B | 10.5B | 9.83B | 10.3B | 10.3B | 10.3B | 10.7B | 5.06B | 5.38B | 5.47B | 6.23B |
| Operating Income | 4.33B | 4.59B | 4.44B | 4.63B | 4.39B | 4.16B | 3.51B | 1.14B | 1.78B | 2.09B | 2.46B |
| EBITDA | 5.61B | 6.22B | 6.84B | 7.24B | 7.19B | 6.86B | 3.10B | 2.73B | 3.14B | 3.17B | 3.55B |
| Net Income | 1.59B | 1.81B | 2.03B | 1.88B | 1.71B | 1.82B | 1.37B | -594M | 471M | 1.21B | 1.60B |
| EPS | 0.72 | 0.81 | 0.91 | 0.84 | 0.77 | 0.81 | 0.61 | -0.26 | 0.05 | 0.13 | 0.18 |
| Balance Sheet | |||||||||||
| Total Assets | 46.4B | 53.1B | 56.7B | 67.0B | 66.6B | 72.0B | 76.4B | 45.3B | 43.6B | 41.4B | 42.2B |
| Total Liabilities | 24.8B | 31.4B | 31.7B | 40.4B | 40.6B | 42.7B | 44.2B | 25.6B | 23.3B | 21.6B | 21.5B |
| Shareholders' Equity | 12.5B | 13.7B | 15.4B | 16.8B | 16.9B | 19.0B | 20.4B | 19.0B | 19.5B | 19.1B | 20.5B |
| Cash & Short-term Investments | 1.61B | 1.65B | 2.81B | 1.79B | 2.00B | 2.75B | 2.35B | 2.56B | 2.05B | 1.58B | 1.85B |
| Total Debt | 14.9B | 19.0B | 19.1B | 27.3B | 25.9B | 27.2B | 27.8B | 15.8B | 13.6B | 11.9B | 11.8B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.57B | 3.94B | 3.74B | 4.26B | 6.55B | 5.08B | 4.20B | 4.46B | 2.45B | 2.59B | 2.02B |
| Capital Expenditure | 1.63B | 8.11B | 3.22B | 2.46B | 2.41B | 2.05B | 1.92B | 1.13B | 923M | 1.44B | 1.10B |
| Free Cash Flow | 1.95B | -4.18B | 523M | 1.80B | 4.14B | 3.03B | 2.28B | 3.32B | 1.52B | 1.15B | 919M |
| Ratios | |||||||||||
| ROE | 12.7% | 13.3% | 13.2% | 11.2% | 10.1% | 9.6% | 6.7% | -3.1% | 2.4% | 6.4% | 7.8% |
| ROA | 3.4% | 3.4% | 3.6% | 2.8% | 2.6% | 2.5% | 1.8% | -1.3% | 1.1% | 2.9% | 3.8% |
| Net Profit Margin | 5.5% | 5.4% | 6.0% | 5.3% | 4.7% | 4.8% | 3.4% | -2.7% | 2.2% | 5.5% | 6.7% |
| Debt to Equity | 1.19x | 1.39x | 1.24x | 1.62x | 1.53x | 1.43x | 1.36x | 0.83x | 0.69x | 0.62x | 0.58x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Fresenius SE & Co KGaA ADR dividends
- Dividend yield
- 2.06%
- Forward dividend
- 0.30 USD
- Payout ratio
- 54.1%
- Ex-dividend date
- May 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 657M | 0.07 | 54.1% |
| 2024 | - | - | - |
| 2023 | EUR 550M | 0.24 | - |
| 2022 | EUR 890M | 0.40 | 64.9% |
| 2021 | EUR 1.07B | 0.48 | 58.7% |
| 2020 | EUR 1.06B | 0.48 | 62.1% |
| 2019 | EUR 952M | 0.43 | 50.6% |
| 2018 | EUR 416M | 0.19 | 20.5% |
| 2017 | EUR 342M | 0.15 | 18.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:2 on Aug 5, 2014.
Who owns Fresenius SE & Co KGaA ADR
- Insiders 0.00%
- Institutions 0.01%
- Public & others 99.99%
- Shares outstanding 2.25B
- Free float 1.64B
Fresenius SE & Co KGaA ADR company profile
- Company name
- Fresenius SE & Co KGaA ADR
- Ticker
- FSNUY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 179,493
- Fiscal year end
- December
- Address
- Else-Kröner-Straße 1, Bad Homburg vor der Höhe, Germany, 61352
- Phone
- 49 6172 6080
- Website
- fresenius.com
About Fresenius SE & Co KGaA ADR
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.
Fresenius SE & Co KGaA ADR management
6- Mr. Michael SenCEO, President & Chairman of Management Board of Fresenius Management SE · born 1968
- Ms. Sara Lisa HennickenCFO & Member of the Management Board - Fresenius Management SE · born 1980
- Dr. Michael Sven Moser Ph.D.Member of Management Board of Fresenius Management SE · born 1976
- Dr. Christian PawluMember of Management Board · born 1978
- Dr. Marc-Alexander MahlMember of Management Board · born 1968
- Mr. Nick StoneSenior VP of Investor Relations & Head of Investor Relations - Fresenius Management SE